BioProcess International Magazine

BioProcess International™ is a monthly magazine with a targeted circulation focused on the creation, scaling, and production of biotherapeutics and biodiagnostics. Every edition delivers the latest, peer-reviewed insights to the global biotherapeutic industry, covering essential topics such as business strategies, political issues, ethical considerations, applications, products, and services necessary for effectively advancing biopharmaceuticals, vaccines, and biodiagnostics from development to manufacturing.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#622151

United States

#315753

Science and Education/Biology

#735

Traffic sources

Monthly visitors

Articles

Imunon looks to DNA vaccine tech to support ovarian cancer immunotherapy

3 days ago | bioprocessintl.com | Dan Stanton |Josh Abbott

Imunon looks to DNA vaccine tech to support ovarian cancer immunotherapyDepositPhotos/drecunThe New Jersey-based biotech is developing non-viral DNA technology for various modalities. Its lead candidate is IMNN-001, an immunotherapy for ovarian cancer, based on the firm’s TheraPlas platform.
Astraveus, NecstGen team up to tackle CGT bottlenecks

1 week ago | bioprocessintl.com | Shreeyashi Ojha

The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen) will assess Paris-based firm Astraveus’ Lakhesys benchtop cell factory, which is a chimeric antigen receptor (CAR)-T therapy manufacturing technology. As per the agreement, the partnership aims to use the cell factory to cut costs and increase efficacy in CAR-T production. Additionally, NecstGen will manufacture lentiviral vectors (LVVs) for R&D.
Amgen ploughing $900m into Ohio production site

1 week ago | bioprocessintl.com | Dan Stanton

Amgen US investmentstock.adobe.comIn March 2024, Amgen opened a 270,000 square-foot facility in New Albany, Ohio supporting its manufacturing network through the addition of assembly and final product packaging capabilities. The site, first touted in 2021, saw an investment of $365 million.
Biopharma players shuffle c-suite ranks

2 weeks ago | bioprocessintl.com | Shreeyashi Ojha

The biotechnology company specializing in chimeric antigen receptor (CAR-Ts) has announced that Paul Stoffels will step down as its CEO while he continues as the non-executive chair of the board of directors. The board expects to appoint Stoffels’ successor within the next 12 months to lead the company into its next phase of growth and innovation as a focused cell therapy company.
With plant ready and client bagged, Lotte launches dedicated ADC biz

2 weeks ago | bioprocessintl.com | Dan Stanton

Lotte launches ADC businessstock.adobe.comIn May 2022, Korean drugmaker Lotte expanded its global presence by buying a Bristol-Myers Squibb’s (BMS) facility in East Syracuse. The site, which now serves as Lotte’s center for its North America contract development and manufacturing organization (CDMO) business, included 40,000 L of biomanufacturing capacity (through eight 5,000 L tanks), as well as an animal health lab, which the firm in 2023 began converting into a full-service ADC suite.
Thermo Fisher reports Q1 growth, charts a steady course for 2025

2 weeks ago | bioprocessintl.com | Shreeyashi Ojha

For the first quarter of 2025, Thermo Fisher Scientific reported revenue of $10.36 billion, with an adjusted operating income of $2.27 billion. The adjusted operating margin for the quarter stood at 21.9%. Marc Casper, CEO of Thermo Fisher, said pharma and biotech had a modest growth, driven by bioproduction and services, amid macroeconomic uncertainty and shifting policies. For 2025, the company aims to strengthen its US manufacturing and ramp up R&D investment.
Merck & Co. bolsters Keytruda production with $1bn US plant

2 weeks ago | bioprocessintl.com | Shreeyashi Ojha

The 470,000 square-foot facility will house laboratory, manufacturing, and warehouse capabilities to support the commercial production of Keytruda and other biologics and therapies, including antibody drug conjugates (ADCs). The facility is expected to employ over 500 people and open by 2028, with production of investigational compounds anticipated to begin by 2030.
PCI bolsters fill/finish capacity with Althea buy

2 weeks ago | bioprocessintl.com | Shreeyashi Ojha

PCI Pharma has acquired aseptic fill/finish contract development and manufacturing organization (CDMO) Althea, a subsidiary of Japan-based Ajinomoto. The San Diego plant consists of seven buildings on three sites and is located close to PCI’s existing clinical trial and manufacturing facilities. The facilities produce prefilled syringes, cartridges, and high potent formulations such as antibody drug conjugates (ADCs). The financials of this transaction were not disclosed.
Blood banks set to transform cell therapy manufacturing future

3 weeks ago | bioprocessintl.com | Brian Gazaille

Cell therapy arguably began with the establishment of blood banks. The world’s first cell-based therapies comprised red blood cells and platelets for transfusion. With the establishment of hospital blood centers in the 1930s and early 1940s, scientists learned how to draw, store, and administer such materials safely. Since then, an entire industry has grown to support blood products, spurring innovation in apheresis technology, aseptic processing, and more.
CDMO Samsung expands with sixth plant amid 25% Q1 revenue growth

3 weeks ago | bioprocessintl.com | Shreeyashi Ojha

The biotech arm of South Korea’s Samsung Group, Samsung Biologics, has four manufacturing plants in the region. During Samsung Biologics’ Q1 financial call, CEO John Rim confirmed that the firm had launched a fifth plant dedicated to antibody-drug conjugates (ADCs). Rim described the news as “another milestone” for the company.